Loading...

We've got a brand new version of Simply Wall St! Try it out

Osoyoos Cannabis

CNSX:OSO
Snowflake Description

Imperfect balance sheet and overvalued.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
OSO
CNSX
CA$2M
Market Cap
  1. Home
  2. CA
  3. Pharmaceuticals & Biotech
Company description

Osoyoos Cannabis Inc., together with its subsidiaries, focuses on the production, extraction, and distribution of cannabis and hemp oils in Canada. The last earnings update was 23 days ago. More info.


Add to Portfolio Compare Print
  • Osoyoos Cannabis has significant price volatility in the past 3 months.
OSO Share Price and Events
7 Day Returns
-17.6%
CNSX:OSO
-0.2%
CA Pharmaceuticals
1.2%
CA Market
1 Year Returns
-
CNSX:OSO
-45.8%
CA Pharmaceuticals
-0.4%
CA Market
OSO Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Osoyoos Cannabis (OSO) -17.6% - - - - -
CA Pharmaceuticals -0.2% -1.8% -21.5% -45.8% 251% 334.4%
CA Market 1.2% 3.3% 0.8% -0.4% 7.4% 4.5%
1 Year Return vs Industry and Market
  • No trading data on OSO.
  • No trading data on OSO.
Price Volatility
Industry
5yr Volatility vs Market

OSO Value

 Is Osoyoos Cannabis undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Osoyoos Cannabis. This is due to cash flow or dividend data being unavailable. The share price is CA$0.07.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Osoyoos Cannabis's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Osoyoos Cannabis's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
CNSX:OSO PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-04-30) in CAD CA$-0.18
CNSX:OSO Share Price ** CNSX (2019-09-19) in CAD CA$0.07
Canada Pharmaceuticals Industry PE Ratio Median Figure of 13 Publicly-Listed Pharmaceuticals Companies 18.72x
Canada Market PE Ratio Median Figure of 540 Publicly-Listed Companies 14.11x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Osoyoos Cannabis.

CNSX:OSO PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= CNSX:OSO Share Price ÷ EPS (both in CAD)

= 0.07 ÷ -0.18

-0.39x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Osoyoos Cannabis is loss making, we can't compare its value to the CA Pharmaceuticals industry average.
  • Osoyoos Cannabis is loss making, we can't compare the value of its earnings to the Canada market.
Price based on expected Growth
Does Osoyoos Cannabis's expected growth come at a high price?
Raw Data
CNSX:OSO PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -0.39x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
Not available
Canada Pharmaceuticals Industry PEG Ratio Median Figure of 7 Publicly-Listed Pharmaceuticals Companies 1.57x
Canada Market PEG Ratio Median Figure of 246 Publicly-Listed Companies 0.95x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Osoyoos Cannabis, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Osoyoos Cannabis's assets?
Raw Data
CNSX:OSO PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-04-30) in CAD CA$0.08
CNSX:OSO Share Price * CNSX (2019-09-19) in CAD CA$0.07
Canada Pharmaceuticals Industry PB Ratio Median Figure of 151 Publicly-Listed Pharmaceuticals Companies 2.32x
Canada Market PB Ratio Median Figure of 2,454 Publicly-Listed Companies 1.44x
CNSX:OSO PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= CNSX:OSO Share Price ÷ Book Value per Share (both in CAD)

= 0.07 ÷ 0.08

0.92x

* Primary Listing of Osoyoos Cannabis.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Osoyoos Cannabis is good value based on assets compared to the CA Pharmaceuticals industry average.
X
Value checks
We assess Osoyoos Cannabis's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Pharmaceuticals industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Pharmaceuticals industry average (and greater than 0)? (1 check)
  5. Osoyoos Cannabis has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

OSO Future Performance

 How is Osoyoos Cannabis expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Osoyoos Cannabis has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
110.6%
Expected Pharmaceuticals industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Osoyoos Cannabis expected to grow at an attractive rate?
  • Unable to compare Osoyoos Cannabis's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare Osoyoos Cannabis's earnings growth to the Canada market average as no estimate data is available.
  • Unable to compare Osoyoos Cannabis's revenue growth to the Canada market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
CNSX:OSO Future Growth Rates Data Sources
Data Point Source Value (per year)
Canada Pharmaceuticals Industry Earnings Growth Rate Market Cap Weighted Average 110.6%
Canada Pharmaceuticals Industry Revenue Growth Rate Market Cap Weighted Average 58.6%
Canada Market Earnings Growth Rate Market Cap Weighted Average 12.8%
Canada Market Revenue Growth Rate Market Cap Weighted Average 5.9%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
CNSX:OSO Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (4 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in CAD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
CNSX:OSO Past Financials Data
Date (Data in CAD Millions) Revenue Cash Flow Net Income *
2019-04-30 -1 -5
2019-01-31 -6
2018-04-30 -1 -3

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if Osoyoos Cannabis is high growth as no earnings estimate data is available.
  • Unable to determine if Osoyoos Cannabis is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
CNSX:OSO Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (4 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from Osoyoos Cannabis Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

CNSX:OSO Past Financials Data
Date (Data in CAD Millions) EPS *
2019-04-30 -0.18
2019-01-31 -0.43
2018-04-30 -0.32

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Osoyoos Cannabis will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. Osoyoos Cannabis's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Pharmaceuticals & Biotech companies here
  2. Osoyoos Cannabis's competitive advantages and company strategy can generally be found in its financial reports archived here.
  3. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess Osoyoos Cannabis's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Canada market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Canada market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Osoyoos Cannabis has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

OSO Past Performance

  How has Osoyoos Cannabis performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Osoyoos Cannabis's growth in the last year to its industry (Pharmaceuticals).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Osoyoos Cannabis does not make a profit and there is insufficient past data to establish if their 5 year on year earnings growth rate was positive.
  • Unable to compare Osoyoos Cannabis's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Osoyoos Cannabis's 1-year growth to the CA Pharmaceuticals industry average as it is not currently profitable.
Earnings and Revenue History
Osoyoos Cannabis's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Osoyoos Cannabis Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

CNSX:OSO Past Revenue, Cash Flow and Net Income Data
Date (Data in CAD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-04-30 -4.93 1.48 0.02
2019-01-31 -6.11 3.31 -0.49
2018-04-30 -2.84 2.22 0.31

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Osoyoos Cannabis has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Osoyoos Cannabis has efficiently used its assets last year compared to the CA Pharmaceuticals industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Osoyoos Cannabis improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Osoyoos Cannabis's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Pharmaceuticals industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Osoyoos Cannabis has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

OSO Health

 How is Osoyoos Cannabis's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Osoyoos Cannabis's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Osoyoos Cannabis is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Osoyoos Cannabis's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Osoyoos Cannabis's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Debt is covered by short term assets, assets are 1.7x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Osoyoos Cannabis Company Filings, last reported 4 months ago.

CNSX:OSO Past Debt and Equity Data
Date (Data in CAD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-04-30 2.64 1.18 1.62
2019-01-31 2.75 1.41 2.14
2018-04-30 4.17 1.45 5.24
  • Osoyoos Cannabis's level of debt (44.8%) compared to net worth is high (greater than 40%).
  • Unable to establish if Osoyoos Cannabis's debt level has increased without past 5-year debt data.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Osoyoos Cannabis has less than a year of cash runway based on current free cash flow.
  • Osoyoos Cannabis has less than a year of cash runway if free cash flow continues to grow at historical rates of 96.2% each year.
X
Financial health checks
We assess Osoyoos Cannabis's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Osoyoos Cannabis has a total score of 2/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

OSO Dividends

 What is Osoyoos Cannabis's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Osoyoos Cannabis dividends.
If you bought CA$2,000 of Osoyoos Cannabis shares you are expected to receive CA$0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Osoyoos Cannabis's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Osoyoos Cannabis's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
CNSX:OSO Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
North America Pharmaceuticals Industry Average Dividend Yield Market Cap Weighted Average of 10 Stocks 2.8%
Canada Market Average Dividend Yield Market Cap Weighted Average of 334 Stocks 3.5%
Canada Minimum Threshold Dividend Yield 10th Percentile 1.2%
Canada Bottom 25% Dividend Yield 25th Percentile 2%
Canada Top 25% Dividend Yield 75th Percentile 5.8%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Osoyoos Cannabis has not reported any payouts.
  • Unable to verify if Osoyoos Cannabis's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Osoyoos Cannabis's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Osoyoos Cannabis has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Osoyoos Cannabis's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.2%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Osoyoos Cannabis afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Osoyoos Cannabis has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

OSO Management

 What is the CEO of Osoyoos Cannabis's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Gerry Goldberg
AGE 75
TENURE AS CEO 0.8 years
CEO Bio

Mr. Gerald Goldberg, also known as Gerry, CPA, CA, serves as Director of CB2 Insights Inc. since August 2019. Mr. Goldberg serves as the Chief Executive officer and Director of Osoyoos Cannabis Inc. since November 1, 2018 and serves as its Chairman. Mr. Goldberg served as Interim Chief Executive Officer of Canada House Wellness Group Inc. from April 15, 2016 to December 22, 2017. Mr. Goldberg has been the President at Leo Acquisitions Corp., since October 2009 and serves as its Chief Executive Officer. He serves as Director at FSD Pharma Inc. He serves as the President of SLF Capital Markets Inc. He serves as a Senior Partner in the accounting firm of Schwartz Levitsky Feldman LLP and serves as its Head of the audit division. Mr. Goldberg served as Chief Executive Officer, President and Chief Financial Officer of Victory Capital Corp. until March 7, 2017. Mr. Goldberg served as the Chief Executive Officer, President of Prime City One Capital Corp. until July 18, 2016. He has been with Schwartz Levitsky Feldman LLP since 1992. Mr. Goldberg has over 30 years of experience in the service, distribution, retail, mining, natural resources and oil & gas, real estate, not-for-profit entities and manufacturing industries, with a strong emphasis in taxation and business advisory services. He served as a Partner in the Predecessor firm of Grant Thornton for over 15 years. He headed the U.S. Public Company audit division of Academy Capital Corp. Mr. Goldberg has been a Director of Gilla Inc. since June 29, 2016. Mr. Goldberg was a Director of Gravitas Financial Inc. since May 12, 2016 until March 2019. He has been a Director at Capricorn Business Acquisitions Inc. since May 7, 2008 and serves as its CFO. He has been a Director of Baymount Incorp since April 2004. He has been Director at Blue Nordic Partners Inc. since June 01, 2016. He has been a Director at Leo Acquisitions Corp. since October 28, 2009. He serves as a Director of Grasslands Entertainment Inc. He served as a Director of Pinetree Capital Ltd., from 2010 to April 29, 2016. He served as Director of Prime City One Capital Corp. since July 2015 until July 18, 2016. Mr. Goldberg served as a Non-Executive Director of Emerge Resources Corp. (formerly Beatrix Ventures Inc) from August 29, 2013 to May 26, 2015. He served as a Director of Victory Capital Corp. until March 7, 2017. He served as a Director of Lakeside Minerals Inc., since December 2008 and InterAmerican Gaming, Inc since January 17, 2012. He served as a Director of Keyuan Petrochemicals, Inc. from July 1, 2010 to June 29, 2012. He served as a Director of Ever-Glory International Group, Inc. from April 1, 2010 to August 21, 2011. He served as a Director at Sagittarius Capital Corporation from April 2007 to August 31, 2009. He served as a Director of Sharing Economy International Inc (aka Cleantech Solutions International, Inc) from March 28, 2008 to April 2009. He served as a Director of Academy Capital Corp. since April 6, 2004 and China Wind Systems, Inc. from March 28, 2008 to April 2009. Mr. Goldberg served as a Director of Jite Technologies Inc. from June 2006 to October 2006. He served as Director of Canada House Wellness Group Inc. since 2016 until January 2017. He is also active in corporate finance and development and has been involved in the structure and design of numerous innovative financing instruments, tax shelters and syndications, both in Canada and the United States. Mr. Goldberg is instrumental in assisting various Canadian, US & Chinese companies in going public in the US & Canada and is involved in structure and design of numerous innovative financing instruments. He is a frequent presenter to the legal, business and financial community on the topic of assisting private companies in listing on the U.S. and Canadian stock exchanges. He is a member of the Institute of Chartered Accountants of Ontario and the Public Accountants Council of Ontario. Mr. Goldberg is a Chartered Professional Accountant. He holds a CTA from the University of South Africa.

CEO Compensation
  • Insufficient data for Gerry to compare compensation growth.
  • Insufficient data for Gerry to establish whether their remuneration is reasonable compared to companies of similar size in Canada.
Management Team

Gerry Goldberg

TITLE
CEO & Chairman
AGE
75
TENURE
0.8 yrs

Rakesh Malhotra

TITLE
Chief Financial Officer
TENURE
0.7 yrs

Tyler Devenyi

TITLE
Chief Operating Officer

Patricia Purdy

TITLE
Secretary
Board of Directors Tenure

Average tenure of the Osoyoos Cannabis board of directors in years:

0.8
Average Tenure
  • The average tenure for the Osoyoos Cannabis board of directors is less than 3 years, this suggests a new board.
Board of Directors

Gerry Goldberg

TITLE
CEO & Chairman
AGE
75

John McMahon

TITLE
Independent Director
TENURE
0.8 yrs

Ernie Eves

TITLE
Independent Director
TENURE
0.8 yrs

Sarah Irwin

TITLE
Independent Director
TENURE
0.8 yrs

Michael Ash

TITLE
Independent Director
TENURE
0.7 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (CA$) Value (CA$)
30. Apr 19 Buy Tyler Devenyi Individual 27. Feb 19 27. Feb 19 20,000 CA$0.25 CA$5,000
11. Mar 19 Sell Lynne Patricia Individual 21. Feb 19 11. Mar 19 -150,000 CA$0.25 CA$-33,889
X
Management checks
We assess Osoyoos Cannabis's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Osoyoos Cannabis has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

OSO News

Simply Wall St News

OSO Company Info

Description

Osoyoos Cannabis Inc., together with its subsidiaries, focuses on the production, extraction, and distribution of cannabis and hemp oils in Canada. It intends to offer oils, creams, gels capsules, and other products. The company is headquartered in Toronto, Canada.

Details
Name: Osoyoos Cannabis Inc.
OSO
Exchange: CNSX
Founded:
CA$2,426,910
34,670,157
Website: http://www.osoyooscannabis.com
Address: Osoyoos Cannabis Inc.
45 Shepherd Avenue East,
Suite 703,
Toronto,
Ontario, M2N 5W9,
Canada
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
CNSX OSO New Class A Shares Canadian National Stock Exchange CA CAD 21. Feb 2019
Number of employees
Current staff
Staff numbers
0
Osoyoos Cannabis employees.
Industry
Pharmaceuticals
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/09/20 01:26
End of day share price update: 2019/09/19 00:00
Last earnings filing: 2019/08/28
Last earnings reported: 2019/04/30
Last annual earnings reported: 2019/04/30


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.